Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
05 Janeiro 2024 - 9:30AM
Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle
disease company focused on advancing innovative life-transforming
therapeutics for people living with genetically driven diseases,
today announced that Joshua Brumm, president and chief executive
officer, is scheduled to present at the 42nd Annual J.P. Morgan
Healthcare Conference in San Francisco on Tuesday, January 9, 2024
at 2:15 p.m. PT (5:15 p.m. ET).
A live webcast will be available in the Investors & Media
section of Dyne’s website
at https://investors.dyne-tx.com/news-and-events/events-and-presentations and
a replay will be accessible for 30 days following the
presentation.
About Dyne Therapeutics
Dyne Therapeutics is a clinical-stage muscle disease company
focused on advancing innovative life-transforming therapeutics for
people living with genetically driven diseases. With its
proprietary FORCE™ platform, Dyne is developing modern
oligonucleotide therapeutics that are designed to overcome
limitations in delivery to muscle tissue. Dyne has a broad pipeline
for serious muscle diseases, including clinical programs for
myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy
(DMD) and a preclinical program for facioscapulohumeral muscular
dystrophy (FSHD). For more information, please
visit https://www.dyne-tx.com, and follow us on X,
LinkedIn and Facebook.
Contact:
Amy Reillyareilly@dyne-tx.com 857-341-1203
Dyne Therapeutics (NASDAQ:DYN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Dyne Therapeutics (NASDAQ:DYN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024